Inhaled Steroids for the Treatment of Asthma and Risk of Osteoporosis


Study Overview

Objective. To determine the effects of fluticasone propionate on bone mineral density (BMD), hypothalamic-pituitary-adrenal (HPA) axis function, and ocular change.

Design. Randomized, double-blind, placebo-controlled trial with an intention-to-treat analysis.

Setting and participants. Participants were recruited from asthma and allergy clinics and evaluated from July 1994 through June 1997. Eligible patients were men aged 18 to 50 years and women aged 18 to 40 years who met the following criteria: ≥6 months of stable and relatively mild asthma (mean forced expiratory volume in 1 second, 82%–85% of predicted) with a low likelihood of requiring oral corticosteroids; normal stimulated cortisol response; normal BMD; no evidence of glaucoma, cataracts, or blindness; no use of corticosteroids for 1 month prior to screening; and a lifetime use of corticosteroids of ≤4 weeks. Patients with Cushing’s or Addison’s disease, any disorder of calcium metabolism, rheumatoid arthritis, osteoarthritis, any metabolic bone disease, anorexia, morbid obesity, unexplained weight loss, or substance abuse were excluded. Patients on hormone replacement therapy or glucocorticoid therapy, or taking vitamin D supplements, digitalis, ketoconazole, or calcitonin also were excluded.

Intervention. Participants were randomized to 88 µg or 440 µg of fluticasone propionate administered via metered-dose inhaler twice daily without a spacer, or placebo.

Main outcome measures. The primary outcomes were BMD, HPA axis functioning, and ocular toxicity. BMD was determined through dual energy x-ray absorptiometry (DEXA) and serum osteocalcin. DEXA scans of the lumbar spine were performed for primary analysis, and proximal femur and total body DEXA scans were performed as a secondary measure. To assess the function of the HPA axis, cortisol production was assessed during a 6-hour cotropin infusion test. Ocular toxicity was evaluated by applanation tonometry, slit-lamp lens examinations, and direct funduscopy. Outcomes were assessed at baseline (during a 21-day, single-blind, placebo run-in period) and then every 24 weeks over the entire course of the study (104 weeks).

Main results. 190 patients were screened and 160 were randomized. Baseline demographic characteristics were similar between the 3 groups. 54 patients were allocated to the placebo group and 40 (74%) completed the trial. 55 patients were assigned to receive fluticasone propionate at 88 µg and 32 (58%) completed the trial, while 51 individuals received fluticasone at 440 µg and 26 (51%) completed the trial. Mean BMD did not differ between the 3 groups at baseline or after 2 years of treatment. Patients randomized to fluticasone 440 µg had a statistically significant difference in peak cotropin-stimulated plasma cortisol at weeks 24 and 52. These differences only represented a 10% to 13% reduction from baseline. This difference was not seen at weeks 76 or 104. No clinically important changes in findings in ophthalmic examination were seen over the duration on the study. 14% of subjects receiving fluticasone 440 µg developed oral candidiasis compared with 2% and 0% in the fluticasone 88 µg and placebo groups, respectively.

Conclusion. Treatment of asthma for 2 years with 88 µg of fluticasone twice daily resulted in similar effects on bone, eye, and HPA axis function when compared with placebo. Larger doses of fluticasone (440 µg twice daily) did transiently reduce serum cortisol levels but had no effect on BMD. Neither dose resulted in any ocular changes.

Commentary

Corticosteroids have an important role in the treatment of severe asthma. Toxicities associated with oral corticosteroids prompted the search for safer long-term alternatives. Inhaled corticosteroids, through topical delivery, are believed to offer the anti-inflammatory properties of oral corticosteroids without the systemic side effects. Inhaled corticosteroids have been so effective in the treatment of asthma that they have become the mainstay of treatment [1]. How-
ever, very few well-designed trials have been conducted to
determine if inhaled steroids produce some of the similar
systemic toxicities of oral corticosteroids over longer treat-
ment periods. Kemp et al have conducted a trial to deter-
mine if long-term use of inhaled corticosteroids for asthma
results in osteoporosis or adrenal insufficiency.

Important systemic toxicities associated with oral cortico-
steroids (ie, osteoporosis, cataracts, HPA axis disruption)
often have resulted in significant morbidity for asthmatics
with uncontrolled disease. This study adds to an emerging
literature that has demonstrated the safety of inhaled corti-
costeroids for both short-term and long-term administration.

It is important to note that different inhaled steroids have
different oral bioavailabilities and selectivity for the gluco-
corticoid receptor, and these results cannot be extrapolated
to other inhaled corticosteroids. However, other studies have
demonstrated that inhaled corticosteroids have little effect
on BMD [2,3]. Therefore, it seems probable that inhaled cor-
ticosteroids in general, particularly low-dose formulations,
do not result in long-term adverse effects on bone metabo-

Applications for Clinical Practice
Fluticasone propionate appears to have no clinically impor-
tant effects on BMD, HPA axis function, or eye function over
a 2-year period. Although the reduction of serum cortisol
levels at higher doses of fluticasone was not clinically signif-
ificant and only transient, it supports the recommendation to
taper asthmatics to the lowest inhaled corticosteroid dose
necessary to achieve optimal symptom control.

—Review by Harvey J. Murff, MD, MPH

References
1. National Asthma Education and Prevention Program.
   Expert panel report: guidelines for the diagnosis and man-
   ageent of asthma: update on selected topics 2002. Bethesda
   02-5074.
   haled corticosteroids and short courses of oral cortico-
   steroids on bone mineral density in asthmatic patients: a
3. Hughes JA Conry BG, Male SM, Eastell R. One year prospec-
   tive open study of the effects of high dose inhaled steroids,
   fluticasone propionate, and budesonide on bone markers